AUGMEDIX INC (AUGX) Fundamental Analysis & Valuation
NASDAQ:AUGX • US05105P1075
Current stock price
2.35 USD
0 (0%)
At close:
2.35 USD
0 (0%)
After Hours:
This AUGX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. AUGX Profitability Analysis
1.1 Basic Checks
- AUGX had negative earnings in the past year.
- In the past year AUGX has reported a negative cash flow from operations.
- AUGX had negative earnings in each of the past 5 years.
- In the past 5 years AUGX always reported negative operating cash flow.
1.2 Ratios
- The Return On Assets of AUGX (-44.44%) is worse than 65.79% of its industry peers.
- The Return On Equity of AUGX (-227.72%) is worse than 81.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.44% | ||
| ROE | -227.72% | ||
| ROIC | N/A |
ROA(3y)-44.98%
ROA(5y)-61.67%
ROE(3y)-606%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- AUGX has a Gross Margin of 48.21%. This is in the lower half of the industry: AUGX underperforms 60.53% of its industry peers.
- In the last couple of years the Gross Margin of AUGX has grown nicely.
- The Profit Margin and Operating Margin are not available for AUGX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.21% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.22%
GM growth 5Y45.73%
2. AUGX Health Analysis
2.1 Basic Checks
- AUGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- AUGX has more shares outstanding than it did 1 year ago.
- Compared to 1 year ago, AUGX has an improved debt to assets ratio.
2.2 Solvency
- AUGX has an Altman-Z score of -2.71. This is a bad value and indicates that AUGX is not financially healthy and even has some risk of bankruptcy.
- AUGX has a worse Altman-Z score (-2.71) than 65.79% of its industry peers.
- A Debt/Equity ratio of 1.48 is on the high side and indicates that AUGX has dependencies on debt financing.
- With a Debt to Equity ratio value of 1.48, AUGX is not doing good in the industry: 84.21% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.48 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.71 |
ROIC/WACCN/A
WACC9%
2.3 Liquidity
- AUGX has a Current Ratio of 1.66. This is a normal value and indicates that AUGX is financially healthy and should not expect problems in meeting its short term obligations.
- AUGX has a Current ratio of 1.66. This is comparable to the rest of the industry: AUGX outperforms 47.37% of its industry peers.
- AUGX has a Quick Ratio of 1.66. This is a normal value and indicates that AUGX is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of AUGX (1.66) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.66 |
3. AUGX Growth Analysis
3.1 Past
- AUGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.66%, which is quite good.
- Looking at the last year, AUGX shows a very strong growth in Revenue. The Revenue has grown by 39.34%.
- The Revenue has been growing by 32.90% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)15.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
Revenue 1Y (TTM)39.34%
Revenue growth 3Y39.62%
Revenue growth 5Y32.9%
Sales Q2Q%26.75%
3.2 Future
- AUGX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.46% yearly.
- AUGX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.58% yearly.
EPS Next Y-20.13%
EPS Next 2Y-3.76%
EPS Next 3Y6.46%
EPS Next 5YN/A
Revenue Next Year18.97%
Revenue Next 2Y22.71%
Revenue Next 3Y11.58%
Revenue Next 5YN/A
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. AUGX Valuation Analysis
4.1 Price/Earnings Ratio
- AUGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AUGX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.76%
EPS Next 3Y6.46%
5. AUGX Dividend Analysis
5.1 Amount
- AUGX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AUGX Fundamentals: All Metrics, Ratios and Statistics
2.35
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-12 2024-08-12/amc
Earnings (Next)11-04 2024-11-04/bmo
Inst Owners72.68%
Inst Owner Change0%
Ins Owners11.72%
Ins Owner Change0%
Market Cap116.16M
Revenue(TTM)51.59M
Net Income(TTM)-23.85M
Analysts80
Price Target3.6 (53.19%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.31%
Min EPS beat(2)4.41%
Max EPS beat(2)12.2%
EPS beat(4)4
Avg EPS beat(4)11.24%
Min EPS beat(4)4.41%
Max EPS beat(4)16.56%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.48%
Min Revenue beat(2)-1.76%
Max Revenue beat(2)-1.2%
Revenue beat(4)1
Avg Revenue beat(4)-0.56%
Min Revenue beat(4)-1.76%
Max Revenue beat(4)0.98%
Revenue beat(8)4
Avg Revenue beat(8)0.08%
Revenue beat(12)5
Avg Revenue beat(12)-0.26%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.74%
EPS NY rev (1m)0%
EPS NY rev (3m)1.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.06%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.64%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.25 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 11.09 | ||
| P/tB | 11.09 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.44
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS1.04
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.44% | ||
| ROE | -227.72% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.21% | ||
| FCFM | N/A |
ROA(3y)-44.98%
ROA(5y)-61.67%
ROE(3y)-606%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.22%
GM growth 5Y45.73%
F-Score5
Asset Turnover0.96
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.48 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 180.82% | ||
| Cap/Sales | 4.95% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.66 | ||
| Altman-Z | -2.71 |
F-Score5
WACC9%
ROIC/WACCN/A
Cap/Depr(3y)178.38%
Cap/Depr(5y)139.24%
Cap/Sales(3y)4.74%
Cap/Sales(5y)4.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
EPS Next Y-20.13%
EPS Next 2Y-3.76%
EPS Next 3Y6.46%
EPS Next 5YN/A
Revenue 1Y (TTM)39.34%
Revenue growth 3Y39.62%
Revenue growth 5Y32.9%
Sales Q2Q%26.75%
Revenue Next Year18.97%
Revenue Next 2Y22.71%
Revenue Next 3Y11.58%
Revenue Next 5YN/A
EBIT growth 1Y-14.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.28%
EBIT Next 3Y9.53%
EBIT Next 5YN/A
FCF growth 1Y12.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.91%
OCF growth 3YN/A
OCF growth 5YN/A
AUGMEDIX INC / AUGX Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for AUGMEDIX INC?
ChartMill assigns a fundamental rating of 2 / 10 to AUGX.
What is the valuation status of AUGMEDIX INC (AUGX) stock?
ChartMill assigns a valuation rating of 0 / 10 to AUGMEDIX INC (AUGX). This can be considered as Overvalued.
How profitable is AUGMEDIX INC (AUGX) stock?
AUGMEDIX INC (AUGX) has a profitability rating of 1 / 10.